Knight Therapeutics Dirección
Dirección controles de criterios 3/4
El CEO de Knight Therapeutics es Samira Sakhia , nombrado en Aug 2016, tiene una permanencia de 8.25 años. compensación anual total es CA$1.33M, compuesta por 38.6% salario y 61.4% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.28% de las acciones de la empresa, por valor de CA$1.45M. La antigüedad media del equipo directivo y de la junta directiva es de 3.4 años y 8.3 años, respectivamente.
Información clave
Samira Sakhia
Chief Executive Officer (CEO)
CA$1.3m
Compensación total
| Porcentaje del salario del CEO | 38.6% |
| Permanencia del CEO | 8.3yrs |
| Participación del CEO | 0.3% |
| Permanencia media de la dirección | 3.4yrs |
| Promedio de permanencia en la Junta Directiva | 8.3yrs |
Actualizaciones recientes de la dirección
Recent updates
Knight Therapeutics Inc. (TSE:GUD) Just Reported Earnings, And Analysts Cut Their Target Price
Nov 09
Does Knight Therapeutics (TSE:GUD) Have A Healthy Balance Sheet?
May 28Shareholders May Not Be So Generous With Knight Therapeutics Inc.'s (TSE:GUD) CEO Compensation And Here's Why
May 07Calculating The Fair Value Of Knight Therapeutics Inc. (TSE:GUD)
Apr 07Read This Before Selling Knight Therapeutics Inc. (TSE:GUD) Shares
Mar 20If You Had Bought Knight Therapeutics' (TSE:GUD) Shares Three Years Ago You Would Be Down 34%
Mar 02Knight Therapeutics (TSE:GUD) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Feb 03
Knight Therapeutics's (TSE:GUD) Earnings Are Growing But Is There More To The Story?
Jan 19What Type Of Shareholders Own The Most Number of Knight Therapeutics Inc. (TSE:GUD) Shares?
Jan 04A Look At The Fair Value Of Knight Therapeutics Inc. (TSE:GUD)
Dec 20The Founder of Knight Therapeutics Inc. (TSE:GUD), Jonathan Goodman, Just Bought A Few More Shares
Dec 07What Type Of Returns Would Knight Therapeutics'(TSE:GUD) Shareholders Have Earned If They Purchased Their SharesYear Ago?
Dec 02Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -CA$31m |
| Jun 30 2024 | n/a | n/a | -CA$21m |
| Mar 31 2024 | n/a | n/a | -CA$17m |
| Dec 31 2023 | CA$1m | CA$514k | -CA$17m |
| Sep 30 2023 | n/a | n/a | -CA$8m |
| Jun 30 2023 | n/a | n/a | -CA$16m |
| Mar 31 2023 | n/a | n/a | -CA$15m |
| Dec 31 2022 | CA$1m | CA$468k | -CA$30m |
| Sep 30 2022 | n/a | n/a | -CA$23m |
| Jun 30 2022 | n/a | n/a | -CA$33m |
| Mar 31 2022 | n/a | n/a | -CA$7m |
| Dec 31 2021 | CA$1m | CA$401k | CA$16m |
| Sep 30 2021 | n/a | n/a | CA$32m |
| Jun 30 2021 | n/a | n/a | CA$59m |
| Mar 31 2021 | n/a | n/a | CA$47m |
| Dec 31 2020 | CA$688k | CA$298k | CA$42m |
| Sep 30 2020 | n/a | n/a | CA$27m |
| Jun 30 2020 | n/a | n/a | CA$6m |
| Mar 31 2020 | n/a | n/a | CA$8m |
| Dec 31 2019 | CA$987k | CA$287k | CA$15m |
| Sep 30 2019 | n/a | n/a | CA$21m |
| Jun 30 2019 | n/a | n/a | CA$37m |
| Mar 31 2019 | n/a | n/a | CA$22m |
| Dec 31 2018 | CA$787k | CA$267k | CA$24m |
| Sep 30 2018 | n/a | n/a | CA$31m |
| Jun 30 2018 | n/a | n/a | CA$22m |
| Mar 31 2018 | n/a | n/a | CA$18m |
| Dec 31 2017 | CA$438k | CA$263k | CA$17m |
Compensación vs. Mercado: La compensación total ($USD953.52K) de Samira está en línea con el promedio de empresas de tamaño similar en el mercado Canadian ($USD1.18M).
Compensación vs. Ingresos: La compensación de Samira ha aumentado mientras la empresa no es rentable.
CEO
Samira Sakhia (56 yo)
8.3yrs
Permanencia
CA$1,331,900
Compensación
Ms. Samira Sakhia, MBA, BCom, CPA, CA, has been the President at Knight Therapeutics Inc. since August 31, 2016 and served as its Chief Financial Officer since October 10, 2017 until March 30, 2020. She ha...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Executive Chairman | 11.8yrs | CA$490.55k | 0.95% CA$ 5.0m | |
| President | 8.3yrs | CA$1.33m | 0.28% CA$ 1.4m | |
| Chief Financial Officer | 4.7yrs | CA$869.82k | 0.042% CA$ 218.9k | |
| Chief Business Officer | 3.7yrs | CA$839.55k | 0.16% CA$ 818.8k | |
| Vice President of Business Development | 3.6yrs | CA$629.57k | sin datos | |
| Vice-President of Manufacturing & Operations | 2.7yrs | sin datos | sin datos | |
| Global Director of Marketing | 1.8yrs | sin datos | 0.0026% CA$ 13.5k | |
| Global Vice President of Human Resources | 3.3yrs | sin datos | 0.020% CA$ 107.0k | |
| Global Vice President of Commercial | 4.1yrs | CA$534.15k | sin datos | |
| Global Vice President of Medical & Clinical | less than a year | sin datos | 0.0030% CA$ 15.9k |
3.4yrs
Permanencia media
Equipo directivo experimentado: El equipo directivo de GUD se considera experimentado (3.4 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Executive Chairman | 11.8yrs | CA$490.55k | 0.95% CA$ 5.0m | |
| President | 8.3yrs | CA$1.33m | 0.28% CA$ 1.4m | |
| Independent Lead Director | 11.8yrs | CA$155.00k | 0.052% CA$ 273.0k | |
| Independent Director | 10.8yrs | CA$127.50k | 0.24% CA$ 1.3m | |
| Independent Director | 4.4yrs | CA$132.43k | 0.012% CA$ 61.5k | |
| Independent Director | 4.4yrs | CA$122.50k | 0.0084% CA$ 44.3k | |
| Independent Director | 5.5yrs | CA$115.00k | 0.0020% CA$ 10.4k |
8.3yrs
Permanencia media
58yo
Promedio de edad
Junta con experiencia: La junta directiva de GUD se considera experimentada (8.3 años de antigüedad promedio).